ClinicalTrials.gg

Program

Anti-CD7 CAR-T Cells RD13-02

Its studies are mostly in Diabetes Mellitus, Type 1, led by Nanjing Bioheng Biotech.

Furthest: early phase 1, since Aug 19, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Bioheng Biotech11 open or runningearly phase 1since Aug 19, 2025Aug 19, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2025First study: early phase 1 study in Diabetes Mellitus, Type 1First studyNCT07142161 · 3 enrolled · China

TargetBeta

CD7 →read by rule
“A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, ”NCIt, by rule

Other programs on CD7

ProgramCompanyFurthest phaseStudies
Autologous Anti-CD7 CAR T Cells PA3-17rulePersonGen BioTherapeutics (Suzhou)phase 26
UTAA07rulePersonGen BioTherapeutics (Suzhou)early phase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07142161Diabetes Mellitus, Type 1 · ChinaEarly 1Active, not recruitingJul 24, 20263

How it is read

Names in the registry

  • “RD13-02 cell infusion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.